Article

pubs.acs.org/joc

Access to N‑Thioalkenyl and N‑(o‑Thio)aryl-benzimidazol-2-ones by
Ring Opening of Thiazolobenzimidazolium and
Benzimidazobenzothiazolium Salts and C−O Bond Cleavage of an
Alkoxide
Federico Andreoli,† Radia Kaid-Slimane,‡ Fabien Coppola,† Daniel Farran,*,† Christian Roussel,*,†
and Nicolas Vanthuyne†
†
Aix Marseille Université, Centrale Marseille, CNRS, iSm2 UMR 7313, 13397 Marseille, France
‡
Laboratoire de synthèse organique appliquée, Département de Chimie, Faculté des Sciences, Université d’Oran (Es Sénia), B.P.
1524, El M’naouer Oran, Algérie
*S Supporting Information

ABSTRACT: We report herein the synthesis of highly functionalized
1,3-dihydro-2H-benzimidazol-2-ones via a ring opening of thiazolo[3,2-
a]benzimidazolium or benzimidazo[2,1-b][1,3]benzothiazol-6-ium salts
and an unusual C−O bond cleavage of an alkoxide. A large variety of
benzimidazolones bearing an original N-thioalkenyl or N-(o-thio)aryl
group was obtained in high yields. The developed chemistry provides
eﬃcient and rapid access to the privileged benzimidazol-2-one scaﬀold.

■ INTRODUCTION

Benzimidazol-2-one is a common molecular framework which
belongs to privileged structures,
i.e., compounds able of
providing useful ligands for more than one type of receptor
or enzyme target by judicious structural modiﬁcations.1 Indeed,
1,3-dihydro-2H-benzimidazol-2-one derivatives exhibit a broad
scope of pharmacological properties, including opioid receptor-
like agonists2 and antagonists,3 reverse transcriptase inhibitors,4
p38 kinase inhibitors,5 respiratory syncytial virus
fusion
inhibitors,6 and progesterone receptor antagonists.7 A survey
of recent literature indicates that investigations in these ﬁelds
remain an active and crucial area of research.8 Furthermore,
besides all these biological activities, this class of compounds
also constitutes attractive building blocks in crystal engineering9
as well as thermoplastic10 and conducting11 polymers.

Conventional synthesis of benzimidazol-2-ones bearing two
diﬀerent substituents on each nitrogen atom requires multistep
manipulations, and three pathways can be envisioned. The ﬁrst
strategy involves formation of the benzimidazole core followed
by regioselective alkylation of either nitrogen atom.7b,12 The
requirement of protecting groups is mandatory in such method.
Another typical approach consists in the nucleophilic displace-
ment of 2-ﬂuoronitrobenzenes with primary amines, subse-
quent reduction, and cyclization using 1,1′-carbonyldiimidazo-
le5a,13 or triphosgene.14 In this case, the scarce commercial
availability of diversely substituted starting material represents a

limitation. Finally, alternative procedures have been reported by
cyclization of o-haloarylureas using palladium15 or copper
catalysis.16 Although these methodologies oﬀer certain
advantages, each suﬀers from some drawback (e.g., low yield,
reaction sequence not straightforward, only few described
examples, harsh conditions) and generates a single function-
alized nitrogen atom.

Access to new therapeutic entities depends greatly on the
discovery of original and pertinent scaﬀolds, connected with the
development of innovative synthetic reactions. In this paper, we
report a straightforward synthesis of unsymmetrically N,N′-
disubstituted 1,3-dihydro-2H-benzimidazol-2-ones 1 and 2 via
thiazolo[3,2-a]benzimidazolium 3 and
ring opening of
benzimidazo[2,1-b][1,3]benzothiazol-6-ium 4 quaternary salts,
respectively (Figure 1).17 The strategy described here allows
modulation of four substituents on the benzimidazole scaﬀolds.
Interestingly,
the ﬁrst example of
installation of a N-thioalkenyl or N-(o-thio)aryl substituent
on these relevant nitrogen-containing heterocycles, and only
two synthetic pathways to N-alkenyl-benzimidazol-2-ones,
simpler structures, are described in the literature.18

this work represents

Received:
January 30, 2015
Published: February 27, 2015

© 2015 American Chemical Society

3233

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry

Article
<para sub=“props”>
those belonging to the methyl group located on the double
bond. It clearly indicates that both heteroatoms are on the same
side of the CC bond, i.e., a Z conﬁguration issuing from the
thiazole moiety.
</para>
<para sub="scope">
The study was then directed toward access to a focused
library of benzimidazol-2-ones 1 with the aim to extend the
scope of our methodology (Table 1). Heterocycles 5 were
allowed to react with a range of halogenated derivatives R3−X
(iodomethane, iodoethane, 1-iodoheptane, benzyl chloride, 3,5-
bis(triﬂuoromethyl)benzyl chloride, or 4-nitrobenzyl chloride)
to furnish the corresponding N-alkylated salts 3 in 68−100%
yield after a simple ﬁltration.
</para>
<para sub="scope">
In the presence of MeONa or BnONa, 3 underwent a ring
opening and we obtained single stereomers of 1,3-dihydro-2H-
benzimidazol-2-ones 1 (R4 = Me) with good to excellent overall
yields (Table 1, entries 1−5 and 9−17). This unprecedented
sequence enabled the preparation of a large series of N-
thioalkenyl benzimidazolones 1 with control of
four sub-
stituents on the heterocyclic ring. Pure products were isolated
without tedious puriﬁcation since the workup consisted in an
extraction in dichloromethane sometimes followed by a quick
ﬁltration on a pad of silica. It is noteworthy that the protocol
utilizes cheap chemicals and allows high atom eﬃciency.
</para>
<para sub="scope">
In order to conﬁrm the cleavage of the alkoxide species, salt
3d (R1 = H, R2 = Me, R3 = Bn) was treated at room
temperature by a freshly prepared solution of sodium benzylate
(Table 1, entry 6). As expected, addition of BnO− provided the
anticipated cis benzimidazolone with subsequent transfer of the
benzyl group to sulfur. This unambiguously demonstrates that
the R4 moiety and the oxygen of the carbonyl on the ﬁnal
heterocycle come from the same alkoxide anion. Furthermore,
salts 3d (R1 = H, R2 = Me, R3 = Bn) and 3a (R1 = H, R2 = Me,
R3 = Me) were allowed to react with BnOH/NaOH at reﬂux
(Table 1, entries 7 and 8). Interestingly, the two geometric
isomers of 1g and 1h have been obtained in a 45/55 (Z/E)
ratio (determined by 1H NMR on the crude material). We
assume that the occurrence of both isomers probably resulted
from isomerization of
the double bond during heating.
However, they were easily separated by column chromatog-
raphy, so that this procedure provided access to the trans
stereomer of benzimidazolone.
</para>
<para sub=“props”>
Compound 1k was crystallized, and a suitable crystal was
used for X-ray diﬀraction.21 The chemical structure of the
isolated benzimidazol-2-ones and the stereochemistry of the
CC double bond were conﬁrmed. Some insight into the solid
state can be gleaned from this analysis: the conformation
adopted is characterized by a dihedral angle of 126° between
the plane containing the original N-thioalkenyl substituent and
the plane containing the heterocyclic ring. In addition, the
crystal packing revealed the presence of
two frozen
atropisomers about the N−Cvinylic bond axis. During HPLC
analysis on chiral stationary phases, neither a plateau nor peak
separation was observed, meaning that the exchange between
these atropisomeric forms is fast in solution.
</para>
During the development of

this work, novel eﬃcient
methodologies to generate benzo[d]imidazo[2,1-b]thiazoles 6
have been published in the literature.22 These structures are
similar to thiazolobenzimidazoles 5, and this encouraged us to
perform a parallel treatment in these series, i.e., synthesis of the
corresponding quaternary salts 4, followed by a ring opening
promoted by an alkoxide (Table 2). This sequence would lead
to N-aryl benzimidazol-2-ones 2, which belong to a class of
molecules possessing pharmacological activities such as heat

3234

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

Figure 1. Synthesis of N-thioalkenyl and N-(o-thio)aryl benzimidazol-
2-ones starting from thiazolobenzimidazole and benzo[d]imidazo-[2,1-
b]benzothiazole, respectively.

■ RESULTS AND DISCUSSION
<para sub="scope">
1,3-Dihydro-2H-benzimidazol-2-ones 1 were prepared using
thiazolo[3,2-a]benzimidazoles 5 as starting materials. Several
thiazolobenzimidazoles 5 are commercially available or can be
obtained from 2-mercaptobenzimidazoles.19 In this work,
heterocycles 5 were eﬃciently synthesized using a one-pot
procedure starting from N-(2-aminophenyl)-thiazoline-2-thio-
nes as we previously reported.20 This protocol led to a broad
structural diversity: R1 represents a hydrogen, a ﬂuorine, or a
triﬂuoromethyl group, and R2 can be an alkyl or an aryl
substituent.21
</para>
<para sub="scope">
With compounds 5 in hand, we ﬁrst examined the sequence
leading to benzimidazol-2-one 1a (Scheme 1). The simplest
</para>
Scheme 1. Synthesis of Benzimidazol-2-one 1a via Ring
Opening of Thiazolobenzimidazolium Salt 2a
<para sub="scope">
thiazolobenzimidazole 5a (R1 = H; R2 = Me) was easily
converted into its corresponding quaternary salt 3a using
methyl iodide in acetone. After solubilization in methanol, this
salt was reacted with sodium methoxide at room temperature
and we were delighted to observe a ring opening generating the
1,3-dihydro-2H-benzimidazol-2-one 1a as a white powder in
71% overall isolated yield.
</para>
<para sub="scope">
the simplicity of

the unprecedented access

Compound 1a is remarkable for

the
synthesis route and for
to a
(thio)vinyl substituent in the benzimidazol-2-one series. The
formation of 1a emphasizes also an uncommon phenomenon:
the H3C−O bond of the alkoxide is cleaved to provide the
oxygen of
the benzimidazolone core and the CH3 group
bonded to the sulfur atom. It means that, in this process, the
methoxide anion acts as a source of methyl group and oxygen
atom.
</para>
<para sub=“props”>
Benzimidazol-2-one 1a was isolated as a single isomer, and a
NOESY experiment was carried out in order to establish the
stereochemistry of the CC double bond.21 This 2D NMR
spectrum revealed that the vinylic hydrogen atom is close to
</para>
The Journal of Organic Chemistry
Table 1. Synthesis of Benzimidazol-2-ones 1 Starting from Thiazolobenzimidazoles 5a

Article

aReagents and conditions: (i) R3−X, acetone (entries 1, 3, 5−8, and 11−17) or no solvent (entries 2 and 9) or acetonitrile (entries 4 and 10), reﬂux
(entries 1−8 and 10−15) or 100 °C (entry 9) or room temperature (entries 16 and 17); (ii) MeONa, MeOH, room temperature (entries 1−5 and
9−16) or BnOH/Na, room temperature (entry 6), or BnOH, NaOH, reﬂux (entries 7−8), or MeONa, MeOH, reﬂux (entry 17). bOverall isolated
yield between brackets.

shock protein 90 inhibitors,23 serotonin 5-HT ligands,24
farnesyltransferase inhibitors,13a and maxi-K channel openers.25
<para sub="scope">
6a (R5 = H) and 6c (R5 = Cl) were directly obtained
according to a reported protocol from 2-mercaptobenzimida-
zole, which is commercially available.22c N-(p-Chloro)benzyl 4b
(R3 = p-Cl-Bn, R5 = H), N-benzyl 4e (R3 = Bn, R5 = Cl), and

N-heptyl 4g (R3 = n-C7H15, R5 = Cl) quaternary salts were then
prepared using analogous procedures to that described for
compounds 3. Interestingly, the treatment of 6a and 6c with
methyl iodide did not proceed quantitatively, even under harsh
conditions (large excess of reagent; heating). TLC of the crude
revealed the presence of a signiﬁcant amount of starting
</para>
3235

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry
Table 2. Synthesis of Benzimidazol-2-ones 2 Starting from Benzo[d]imidazo-[2,1-b]benzothiazoles 6a

Article

aReagents and conditions: (i) R3−X, pentan-3-one (entries 1−4 and 7) or no solvent (entries 5 and 6), reﬂux (entries 1−4 and 7) or 90 °C (entries
5 and 6); (ii) MeONa/MeOH (entries 1−3, 5, and 7) or EtOH/Na (entries 4 and 6), 40 °C (entries 1, 2, and 7), or reﬂux (entries 3 and 5), or
room temperature (entries 4 and 6). bOverall isolated yield between brackets.
<para sub="scope">
the nucleophilicity of

material indicating a reversible reaction. We hypothesized that
this was probably due to the lower basicity of the involved
nitrogen atom and/or
the iodine
counterion which could provide a demethylation reaction.26
To tackle this issue, methyl p-toluenesulfonate was chosen as
alkylating agent, and the desired salts 4a (R3 = Me, R5 = H) and
4c (R3 = Me, R5 = Cl) were isolated in 77% and 87% yield,
respectively, after puriﬁcation.
</para>
<para sub="scope">
Sodium methoxide was then allowed to react with [3,1]-
benzimidazo[2,1-b][1,3]benzothiazol-6-ium 4a−c, 4e, and 4g
(Table 2, entries 1−3, 5, and 7, respectively) leading to the
corresponding N-aryl benzimidazolones 2 with good to
excellent yields, except 2g for which we were not able to
optimize the puriﬁcation step on column chromatography.
Moreover, sodium ethoxide was tested on derivatives 4c (Table
2, entry 4) and 4e (Table 2, entry 6). A preliminary attempt on
4c was carried out at 70 °C and furnished a mixture of 2c (R3 =
Me, R4 = Me, R5 = Cl) and 2d (R3 = Me, R4 = Et, R5 = Cl). We
the formation of compound 2c probably
postulated that
resulted from a demethylation of the starting quaternary salts.
Consequently,
room
temperature, yielding the sole compound 2d. Similar
experimental conditions were used for the synthesis of 2f,
which was isolated in very good yield.

the ring opening was performed at
</para>
<para sub=“ques”>
A plausible mechanism of this unprecedented ring opening is
depicted in Scheme 2. In a ﬁrst step, the nucleophilic alcoholate
species attacks the quaternary sp2 carbon bonded to three
heteroatoms. The R4−O bond of the alcoholate is then cleaved
</para>
Scheme 2. Possible Mechanism for the Ring Opening
<para sub=“ques”>
to provide the oxygen atom of the benzimidazolone core and
R4 bonded to the sulfur atom. On the basis of the observed
results, Scheme 2 provides a postulated mechanism as a
concerted process. However, depending on the actual bond
breaking, the formation of thiolate and oxonium as an intimate
ion pair can be also envisioned. Further studies are underway to
trace the occurrence of disulﬁde moieties which would indicate
a stepwise process accompanying the concerted one.
</para>
■ CONCLUSION

In summary, we developed and exempliﬁed a powerful
sequence for accessing unprecedented N-thioalkenyl and N-
(o-thio)aryl 1,3-dihydro-2H-benzimidazol-2-ones. The process
involves a ring opening of a quaternary salt (thiazolo[3,2-
a]benzimidazolium or benzimidazo[2,1-b][1,3]benzothiazol-6-
ium) and a concomitant C−O bond cleavage of the addition
product. Taking into account
the 1,3-dihydro-2H-
benzimidazol-2-one scaﬀold belongs to the few privileged

that

3236

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry

structures, this study opens the way to an unexplored chemical
space for future biological screenings.

■ EXPERIMENTAL SECTION
<para sub=“exp”>
General

Information. Commercially reagent-grade chemicals
were used as received without additional puriﬁcation. All reactions
were followed by TLC (Kieselgel 60 F-254). TLC spots were
visualized with UV light and/or by staining with potassium
permanganate or phosphomolybdic acid solution followed by heating.
Column chromatography was performed on silica gel (60−200 mesh).
Melting points are uncorrected. Chemicals shifts in 1H NMR and 13C
NMR spectra are reported as part per million downshift
from
tetramethylsilane, and coupling constants are reported in hertz. When
necessary, resonances were assigned using two-dimensional experi-
ments (COSY, HMBC, HSQC). HRMS (ESI) were recorded on a
TOF mass spectrometer.
Synthesis of 3-(2-Aminophenyl)-1,3-thiazole-2(3H)-thione 7.
General procedure for compounds 7k−o: Triethylamine (20 mmol)
was added dropwise to a suspension of 1,2-diaminobenzene (10
mmol) in CS2 (23 mL). After 2 h, the precipitate was ﬁltered, washed
with Et2O, and dried to yield quantitatively the dithiocarbamate salt.
This solid was then suspended in ethanol (30 mL), and a solution of
α-halogenated ketone (10 mmol; 2-bromoacetophenone for 7k; 2-
bromo-4′-ﬂuoroacetophenone for 7l; 2-bromo-4′-chloroacetophenone
for 7m; 2-bromo-4′-methoxyacetophenone for 7n; 2-bromo-2′-
acetonaphthone for 7o) in ethanol (30 mL) was added dropwise at
0 °C, followed by addition of HCl 37% (3 mL) dropwise at 0 °C. The
mixture was then heated at reﬂux for 1 h, whereupon water (100 mL)
was added. The mixture was then extracted with dichloromethane (3 ×
100 mL), and the organic layer was washed with water (3 × 100 mL),
dried on MgSO4, and evaporated under reduced pressure. The desired
compound was then isolated after crystallization in ethanol.

3-(2-Aminophenyl)-4-phenyl-1,3-thiazole-2(3H)-thione, 7k. Yield:
86% (2.620 g). White solid. Mp = 189 °C. 1H NMR (400 MHz,
DMSO-d6): δ 5.12 (2H, br s, NH2), 6.42−6.47 (1H, m, arom), 6.70−
6.76 (2H, m, arom), 6.99−7.05 (1H, m, arom), 7.17 (1H, s, H5),
7.21−7.31 (5H, m, arom). 13C NMR (100 MHz, DMSO-d6): δ 110.3,
116.0, 116.2, 122.9, 128.1 (2C), 128.4 (2C), 129.0, 129.2, 129.8, 130.6,
144.5, 145.0, 188.5. HRMS m/z calcd C15H13N2S2 [M + H]+:
285.0514; found 285.0514.
3-(2-Aminophenyl)-4-(4-ﬂuorophenyl)-1,3-thiazole-2(3H)-thione,
7l. Yield: 77% (2.477 g). White solid. Mp = 139 °C. 1H NMR (400
MHz, DMSO-d6): δ 5.09 (2H, br s, NH2), 6.44−6.49 (1H, m, arom),
6.70−6.76 (2H, m, arom), 6.77−6.81 (2H, m, arom), 7.00−7.09 (2H,
m, arom + H5), 7.15−7.21 (2H, m, arom). 13C NMR (100 MHz,
DMSO-d6): δ 109.3, 113.5, 113.8, 116.0, 116.2, 122.9, 129.2, 129.8,
129.9 (2C), 130.5, 144.4, 145.0, 159.6, 188.4. HRMS: ionization of the
sample under various conditions failed.
3-(2-Aminophenyl)-4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione,
7m. Yield: 61% (2.730 g). White solid. Mp = 231 °C. 1H NMR (400
MHz, DMSO-d6): δ 5.15 (2H, br s, NH2), 6.44−6.50 (1H, m, arom),
6.72 (1H, dd, J = 8.2, J = 1.2, arom), 6.77 (1H, dd, J = 7.9, J = 1.5,
arom), 7.01−7.07 (1H, m, arom), 7.22 (1H, s, H5), 7.24−7.36 (4H,
m, arom). 13C NMR (100 MHz, DMSO-d6): δ 110.9, 116.0, 116.2,
122.5, 128.2 (2C), 129.2, 129.4, 130.0, 130.3 (2C), 133.8, 143.2, 145.0,
188.6. HRMS m/z calcd C15H12N2S2Cl [M + H]+: 319.0124; found
319.0126.
3-(2-Aminophenyl)-4-(4-methoxyphenyl)-1,3-thiazole-2(3H)-thi-
one, 7n. Yield: 75% (6.660 g). White solid. Mp = 164 °C. 1H NMR
(400 MHz, DMSO-d6): δ 3.69 (3H, s, OCH3), 5.09 (2H, br s, NH2),
6.43−6.50 (1H, m, arom), 6.70−6.75 (2H, m, arom), 6.77−6.82 (2H,
m, arom), 7.00−7.06 (1H, m, arom), 7.07 (1H, s, H5), 7.16−7.21
(2H, m, arom). 13C NMR (100 MHz, DMSO-d6): δ 55.1, 109.3, 113.5
(2C), 116.0, 116.2, 122.9 (2C), 129.2, 129.8, 129.9 (2C), 144.4, 145.0,
159.6, 188.4. HRMS m/z calcd C16H15N2OS2 [M + H]+: 315.0620;
found 315.0622.
3-(2-Aminophenyl)-4-(naphthalen-2-yl)-1,3-thiazole-2(3H)-thi-
one, 7o. Yield: 49% (3.900 g). White solid. Mp = 163 °C. 1H NMR
(400 MHz, DMSO-d6): δ 5.20 (2H, br s, NH2), 6.39−6.45 (1H, m,
arom), 6.73 (1H, dd, J = 8.2, J = 1.2, arom), 6.79 (1H, dd, J = 7.8, J =
</para>
Article
<para sub=“exp”>
1.4, arom), 6.97−7.03 (1H, m, arom), 7.31 (1H, dd, J = 8.6, J = 1.7,
arom), 7.31 (1H, s, H5), 7.48−7.55 (2H, m, arom), 7.76 (1H, d, J =
12.4, arom), 7.76−7.87 (2H, m, arom), 7.90 (1H, s, arom). 13C NMR
(100 MHz, DMSO-d6): δ 110.8, 116.1, 116.2, 122.9, 125.5, 126.6,
127.0, 127.5 (2C), 128.1 (2C), 128.1, 129.2, 129.9, 132.2, 132.6, 144.5,
145.1, 188.6. HRMS m/z calcd C19H15N2S2 [M + H]+: 335.0671;
found 335.0669.

Synthesis of [1,3]Thiazolo[3,2-a]benzimidazole 5. General
procedure: Compound 7 (2 mmol) was solubilized in acetone (10
mL), and methyl iodide (20 mmol) was added. After 12 h, the solvent
was removed under reduced pressure to aﬀord quantitatively the
corresponding thiazolium iodide. The residue was heated at reﬂux for
12−24 h in methanol (20 mL), whereupon the solvent was removed
under reduced pressure to aﬀord quantitatively the corresponding
thiazolo[3,2-a]benzimidazolium iodide. The crude was then treated
with a saturated solution of NaHCO3 (20 mL). The mixture was
extracted with dichloromethane (3 × 10 mL), and the organic layer
was dried on MgSO4 and evaporated to give the desired compound.
3-Phenyl[1,3]thiazolo[3,2-a]benzimidazole, 5k. Yield: 69% (603
mg). White solid. Mp = 147 °C. 1H NMR (400 MHz, CDCl3) δ 6.70
(1H, s, H5), 7.08−7.14 (1H, m, arom), 7.23 (1H, d, J = 8.2, arom),
7.34−7.40 (1H, m, arom), 7.56−7.69 (5H, m, arom), 7.82 (1H, d, J =
8.2, arom). 13C NMR (100 MHz, CDCl3) δ 108.3, 112.1, 118.8, 121.2,
124.2, 129.0, 129.1 (2C), 129.2 (2C), 129.7, 130.5, 134.6, 146.7, 156.8.
HRMS m/z calcd C15H11N2S [M + H]+: 251.0637; found 251.0638.
3-(4-Fluorophenyl)[1,3]thiazolo[3,2-a]benzimidazole, 5l. Yield:
91% (300 mg). White solid. Mp = 152 °C. 1H NMR (400 MHz,
CDCl3): δ 6.76 (1H, s, H5), 7.12−7.20 (2H, m, arom), 7.27−7.34
(2H, m, arom), 7.37−7.43 (1H, m, arom), 7.63−7.69 (2H, m, arom),
7.85 (1H, d, J = 8.3, arom). 13C NMR (100 MHz, CDCl3): δ 109.3,
111.9, 116.5, 116.7, 118.5, 121.7, 124.7, 124.9, 129.4, 131.2, 131.3,
133.6, 145.4, 156.3, 164.1 (d, J = 251). HRMS m/z calcd C15H10N2SF
[M + H]+: 269.0543; found 269.0543.

3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a]benzimidazole, 5m. Yield:
86% (160 mg). White solid. Mp = 200 °C. 1H NMR (400 MHz,
CDCl3): δ 6.85 (1H, s, H5), 7.16−7.25 (2H, m, arom), 7.41−7.47
(1H, m, arom), 7.58−7.65 (4H, m, arom), 7.87 (1H, d, J = 8.3, arom).
13C NMR (100 MHz, CDCl3): δ 110.3, 112.2, 118.1, 122.2, 125.2,
126.9, 129.0, 129.8 (2C), 130.5 (2C), 131.5, 133.7, 137.2, 156.1.
HRMS m/z calcd C15H10N2SCl [M + H]+: 285.0247; found 285.0248.
3-(4-Methoxyphenyl)[1,3]thiazolo[3,2-a]benzimidazole, 5n.
Yield: 55% (450 mg). White solid. Mp = 153 °C. 1H NMR (400
MHz, CDCl3): δ 3.92 (3H, s, OCH3), 6.58 (1H, s, H5), 7.06−7.11
(3H, m, arom), 7.24 (1H, d, J = 8.2, arom), 7.32−7.37 (1H, m, arom),
7.55−7.60 (2H, m, arom), 7.80 (1H, d, J = 8.2, arom). 13C NMR (100
MHz, CDCl3): δ 55.6, 107.1, 111.9, 114.6 (2C), 118.9, 120.9, 121.4,
123.9, 129.9, 130.5 (2C), 134.4, 147.4, 156.9, 161.2. HRMS m/z calcd
C16H13N2OS [M + H]+: 281.0743; found 281.0743.
3-(Naphthalen-2-yl)[1,3]thiazolo[3,2-a]benzimidazole, 5o. Yield:
33% (300 mg). White solid. Mp = 164 °C. 1H NMR (400 MHz,
CDCl3): δ 6.78 (1H, s, H5), 7.03−7.09 (1H, m, arom), 7.24 (1H, d, J
= 8.2, arom), 7.33−7.38 (1H, m, arom), 7.59−7.67 (2H, m, arom),
7.83 (1H, dd, J = 8.4, J = 1.8, arom), 7.83 (1H, d, J = 8.5, arom), 7.91−
8.01 (2H, m, arom), 8.05 (1H, d, J = 8.5, arom), 8.16 (1H, s, arom).
13C NMR (100 MHz, CDCl3): δ 108.5, 112.2, 118.8, 121.2, 124.1,
125.7, 126.4, 127.4, 127.7, 128.2, 128.5, 128.9, 129.1, 129.9, 133.1,
134.0, 134.6, 147.0, 156.9. HRMS m/z calcd C19H13N2S [M + H]+:
301.0794; found 301.0794.
Synthesis of [1,3]thiazolo[3,2-a]benzimidazol-9-ium 3. For
experimental procedures and characterization data for compounds 3a−
f and 3p−q, see ref 17.

9-Benzyl-3-tert-butyl[1,3]thiazolo[3,2-a]benzimidazol-9-ium
chloride, 3i. A solution of 3-tert-butyl-thiazolo[3,2-a]benzimidazole 5i
(349 mg, 1.52 mmol) in benzyl chloride (2 mL) was stirred at 100 °C
for 24 h. The crude was puriﬁed by column chromatography (eluent
CH2Cl2/MeOH 9:1) providing the desired compound (540 mg).
Yield: 100%. Pale orange solid. Mp = 177 °C. 1H NMR (400 MHz,
CD3OD): δ 1.69 (9H, s, CH3), 5.86 (2H, s, NCH2), 7.36 (1H, s, H5),
7.48 (3H, s, arom), 7.61 (2H, s, arom), 7.75−7.87 (2H, m, arom), 8.18
(1H, br d, J = 6.1, arom), 8.44 (1H, br d, J = 6.2, arom). 13C NMR
</para>
3237

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry

Article
<para sub=“exp”>
(100 MHz, CD3OD): δ 29.0, 34.8, 51.9, 111.7, 114.2, 118.0, 126.3,
128.5, 129.0, 130.5 (2C), 130.8 (3C), 132.5, 137.9, 147.7, 157.8.
HRMS m/z calcd C20H21N2S+ [M]+: 321.1420; found 321.1415.

9-[3,5-Bis(triﬂuoromethyl)benzyl]-3-tert-butyl[1,3]thiazolo[3,2-a]-
benzimidazol-9-ium chloride, 3j. To a solution of 3-tert-butyl-
thiazolo[3,2-a]benzimidazole 5i (273 mg, 1.19 mmol) in acetonitrile
(3 mL), 3,5-bis(triﬂuoromethyl)benzyl chloride (935 mg, 3.56 mmol)
was added, and the mixture was stirred at reﬂux for 24 h. The crude
was puriﬁed by column chromatography (eluent CH2Cl2/MeOH 9:1)
providing the desired compound (395 mg). Yield: 68%. White solid.
Mp = 161 °C. 1H NMR (400 MHz, CD3OD): δ 1.71 (9H, s, CH3),
6.04 (2H, s, NCH2), 7.34 (1H, s, H5), 7.75−7.84 (2H, m, arom),
8.03−8.06 (1H, m, arom), 8.11 (1H, s, arom), 8.23 (2H, s, arom),
8.43−8.47 (1H, m, arom). 13C NMR (150 MHz, CD3OD): δ 29.0
(3C), 35.0, 50.5, 111.3, 113.9, 118.3, 124.3 (m), 124.5 (2C, q, J =
272), 126.5, 128.6, 129.4, 130.9 (2C, m), 133.7 (2C, q, J = 34), 136.6,
+ [M]+: 457.1168;
137.9, 148.5, 158.6. HRMS m/z calcd C22H19N2SF6
found 457.1165.
General procedure for compounds 3k−o: To a solution of the
corresponding compound 5 (1 mmol) in acetone (3 mL), methyl
iodide (10 mmol) was added, and the mixture was stirred at reﬂux (3 h
for 3k and 3o; 5 h for 3l−n). The desired compound was then isolated
by ﬁltration.
9-Methyl-3-phenyl[1,3]thiazolo[3,2-a]benzimidazol-9-ium Io-
dide, 3k. Yield: 100% (87 mg). White solid. Mp = 202 °C. 1H
NMR (400 MHz, CD3OD): δ 4.24 (3H, s, NCH3), 7.35 (1H, d, J =
8.4, arom), 7.48 (1H, td, J = 8.4, J = 0.9, arom), 7.65 (1H, s, H5),
7.69−7.87 (6H, m, arom), 8.01 (1H, d, J = 8.5, arom). 13C NMR (100
MHz, CD3OD): δ 33.7, 113.8, 114.7, 114.8, 125.9, 128.4, 128.7, 130.6
(2C), 130.8, 130.9 (2C), 132.6, 137.7, 138.5, 156.9. HRMS m/z calcd
C16H13N2S+ [M]+: 265.0793; found 265.0793.
3-(4-Fluorophenyl)-9-methyl[1,3]thiazolo[3,2-a]benzimidazol-9-
ium Iodide, 3l. Yield: 97% (159 mg). White solid. Mp = 264 °C. 1H
NMR (400 MHz, CD3OD): δ 4.11 (3H, s, NCH3), 7.20 (1H, d, J =
8.4, arom), 7.31−7.41 (3H, m, arom), 7.53 (1H, s, H5), 7.60−7.65
(1H, m, arom), 7.73−7.79 (2H, m, arom), 7.88 (1H, d, J = 8.4, arom).
13C NMR (75 MHz, CD3OD): δ 33.6, 113.8, 113.8, 114.6, 115.2,
117.6, 117.9, 124.6, 124.6, 126.0, 128.7, 133.4, 136.7, 138.4, 156.9,
166.0 (d, J = 250.5). HRMS m/z calcd C16H12N2SF+ [M]+: 283.0699;
found 283.0700.
3-(4-Chlorophenyl)-9-methyl[1,3]thiazolo[3,2-a]benzimidazol-9-
ium Iodide, 3m. Yield: 98% (73 mg). White solid. Mp = 276 °C. 1H
NMR (400 MHz, CD3OD): δ 4.24 (3H, s, NCH3), 7.39 (1H, d, J =
8.5, arom), 7.53 (1H, t, J = 7.6, arom), 7.69 (1H, s, H5), 7.73−7.87
(5H, m, arom), 8.02 (1H, d, J = 8.5, arom). 13C NMR (75 MHz,
CD3OD): δ 33.6, 113.8, 114.7, 115.4, 126.1, 127.0, 128.5, 130.9 (2C),
131.7, 132.5 (2C), 136.6, 138.4, 138.9, 157.0. HRMS m/z calcd
C16H12N2SCl+ [M]+: 299.0404; found 299.0404.

3-(4-Methoxyphenyl)-9-methyl[1,3]thiazolo[3,2-a]benzimidazol-
9-ium Iodide, 3n. Yield: 100% (163 mg). Pale brown solid. Mp = 216
°C. 1H NMR (400 MHz, CD3OD): δ 3.97 (3H, s, OCH3), 4.22 (3H,
s, NCH3), 7.22−7.28 (2H, m, arom), 7.38 (1H, d, J = 8.5, arom),
7.46−7.52 (1H, m, arom), 7.54 (1H, s, H5), 7.71−7.77 (3H, m,
arom), 8.01 (1H, d, J = 8.4, arom). 13C NMR (75 MHz, CD3OD): δ
33.6, 56.2, 113.7, 113.9, 114.7, 115.9 (2C), 120.1, 125.9, 128.4, 128.7,
132.4 (2C), 137.9, 138.4, 156.8, 163.6. HRMS m/z calcd
C17H15N2OS+ [M]+: 295.0899; found 295.0900.
9-Methyl-3-(naphthalen-2-yl)[1,3]thiazolo[3,2-a]benzimidazol-9-
ium Iodide, 3o. Yield: 100% (91 mg). Pale brown solid. Mp = 193 °C.
1H NMR (400 MHz, CD3OD): δ 4.25 (3H, s, NCH3), 7.30 (1H, d, J =
8.5, arom), 7.42 (1H, t, J = 8.3, arom), 7.65−7.76 (4H, m, arom +
H5), 7.85 (1H, dd, J = 8.5, J = 1.7, arom), 8.01 (1H, d, J = 8.4, arom),
8.07 (2H, t, J = 7.3, arom), 8.20 (1H, d, J = 8.5, arom), 8.38 (1H, s,
arom). 13C NMR (100 MHz, CD3OD): δ 33.7, 113.8, 114.8, 115.0,
125.5, 125.9, 126.8, 128.4, 128.7, 128.7, 129.2, 129.3, 129.6, 130.4,
131.2, 134.4, 135.7, 137.8, 138.4, 157.0. HRMS m/z calcd C20H15N2S+
[M]+: 315.0950; found 315.0950.
Synthesis of Benzo[d]imidazo-[2,1-b]benzothiazoles 4. Gen-
eral procedure for compounds 4a−c and 4g: To a solution of the
corresponding compound 6 (1 mmol) in pentan-3-one (1−4 mL),

alkylating reagent (for 4a and 4c, 10 mmol of methyl p-
toluenesulfonate; for 4b, 8 mmol of p-chlorobenzyl chloride; for 4g,
12 mmol of 1-iodoheptane) was added, and the mixture was stirred at
reﬂux (for 4a, 20 h; for 4b, 24 h; for 4c, overnight; for 4g, 48 h). The
desired compound was then isolated by ﬁltration and washed with
acetone (for 4b, before this ﬁltration, excess of p-chlorobenzyl chloride
was removed under vacuum).

6-Methyl[3,1]benzimidazo[2,1-b][1,3]benzothiazol-6-ium 4-
Methylbenzenesulfonate, 4a. Yield: 58% (2.354 g). White solid.
Mp = 245−247 °C. 1H NMR (400 MHz, CD3OD): δ 2.38 (3H, s,
CH3 tos), 4.25 (3H, s, NCH3), 7.23 (2H, d, J = 8.0, arom), 7.70 (2H,
d, J = 8.1, arom), 7.78 (1H, t, J = 7.8, arom), 7.82−7.89 (2H, m,
arom), 7.94 (1H, t, J = 7.8, arom), 8.05−8.11 (1H, m, arom), 8.31
(1H, d, J = 8.2, arom), 8.61−8.68 (2H, m, arom). 13C NMR (100
MHz, CD3OD): δ 21.3, 34.0, 114.0, 114.7, 116.4, 126.7, 126.9 (2C),
127.3, 128.4, 128.5, 128.9, 129.7, 129.8 (2C), 130.2, 133.9, 137.9,
141.6, 143.6, 156.6. HRMS m/z calcd C14H11N2S+ [M]+: 239.0637;
found 239.0639.

6-(4-Chlorobenzyl)[3,1]benzimidazo[2,1-b][1,3]benzothiazol-6-
ium Chloride, 4b. Yield: 70% (457 mg). Pale brown solid. Mp = 240
°C (decomposition). 1H NMR (400 MHz, CD3OD): δ 5.87 (2H, s,
NCH2), 7.54 (2H, d, J = 8.5, arom), 7.63 (2H, d, J = 8.4, arom), 7.71
(1H, t, J = 7.9, arom), 7.82−7.87 (2H, m, arom), 7.89 (1H, t, J = 7.9,
arom), 8.10−8.16 (1H, m, arom), 8.18 (1H, d, J = 8.2, arom), 8.61−
8.67 (2H, m, arom). 13C NMR (100 MHz, CD3OD): δ 51.3, 114.3,
114.9, 116.5, 126.5, 127.6, 128.6 (2C), 129.2, 130.1, 130.2, 130.8 (2C),
131.1, 132.7 (2C), 133.6, 137.3, 137.5, 156.0. HRMS m/z calcd
C20H14N2SCl+ [M]+: 349.0561; found 349.0564.

2-Chloro-6-methyl[3,1]benzimidazo[2,1-b][1,3]benzothiazol-6-
ium 4-Methylbenzenesulfonate, 4c. Yield: 87% (785 mg). White
solid. Mp = 247 °C (decomposition). 1H NMR (400 MHz, CD3OD):
δ 2.32 (3H, s, CH3), 4.21 (3H, s, NCH3), 7.14 (2H, d, J = 8.0, arom),
7.60 (2H, d, J = 8.2, arom), 7.74 (1H, dd, J = 8.8, J = 1.8, arom), 7.78−
7.86 (2H, m, arom), 8.01−8.06 (1H, m, arom), 8.24 (1H, d, J = 8.8,
arom), 8.59−8.64 (1H, m, arom), 8.67 (1H, d, J = 1.8). 13C NMR
(100 MHz, CD3OD): δ 21.3, 33.9, 114.0, 114.8, 116.7, 126.8 (2C),
127.5, 127.8, 128.3, 128.6, 128.7, 128.8, 129.7 (2C), 134.7, 136.3,
137.8, 141.5, 143.6, 157.4. HRMS m/z calcd C14H10N2SCl+ [M]+:
273.0248; found 273.0251.
2-Chloro-6-heptyl[3,1]benzimidazo[2,1-b][1,3]benzothiazol-6-
ium Iodide, 4g. Yield: 65% (583 mg). White solid. Mp = 255 °C. 1H
NMR (400 MHz, CD3OD): δ 0.87−0.93 (3H, m, CH3), 1.28−1.57
(8H, m, 4CH2), 2.05−2.16 (2H, m, CH2), 4.69 (2H, t, J = 7.3, NCH2),
7.77 (1H, dd, J = 8.8, J = 1.8, arom), 7.80−7.87 (2H, m, arom), 8.09−
8.15 (1H, m, arom), 8.30 (1H, d, J = 8.8, arom), 8.64−8.69 (1H, m,
arom), 8.72 (1H, d, J = 1.8, arom). 13C NMR (100 MHz, CD3OD): δ
14.4, 23.6, 27.7, 29.1, 29.9, 32.8, 49.0, 114.2, 115.1, 116.9, 127.6, 127.9,
128.3, 128.7, 128.8, 129.1, 134.8, 136.4, 137.3, 156.7. HRMS m/z calcd
C20H22N2SCl+ [M + H]+: 357.1187; found 357.1184.

6-Benzyl-2-chloro[3,1]benzimidazo[2,1-b][1,3]benzothiazol-6-
ium Bromide, 4e. A solution of 2-chlorobenzo[d]benzo[4,5]imidazo-
[2,1-b]thiazole 6c (128 mg, 0.49 mmol) in benzyl bromide (2 mL,
16.92 mmol) was added, and the mixture was stirred at 90 °C for 4 h.
After cooling at room temperature, diethyl ether (10 mL) was added
and the desired compound was then isolated by ﬁltration (210
mg).Yield: 100%. White solid. Mp = 246 °C (decomposition). 1H
NMR (400 MHz, CD3OD): δ 5.97 (2H, s, NCH2), 7.52−7.73 (6H, m,
arom), 7.82−7.89 (2H, m, arom), 8.07−8.19 (2H, m, arom), 8.65−
8.72 (2H, m, arom). 13C NMR (100 MHz, CD3OD): δ 52.2, 103.8,
114.3, 115.0, 116.7, 127.5, 127.7, 128.8, 129.1, 130.8 (2C), 131.5 (3C),
131.9, 134.2, 136.3, 137.5, 156.5. HRMS m/z calcd C20H14N2SCl+
[M]+: 349.0561; found 349.0561.
Synthesis of Benzimidazol-2-one 1. For experimental proce-
dures and characterization data for compounds 1a−h and 1p−q, see
ref 17.

Procedure to access to compound 1g1 as a single isomer (Table 1,
entry 6): To a solution of 9-benzyl-3-methyl[1,3]thiazolo[3,2-
a]benzimidazol-9-ium chloride 3d (65 mg, 0.21 mmol) in benzyl
alcohol (3 mL), 1.5 mL of a freshly prepared solution of sodium
benzylate (prepared by addition of sodium [22 mg, 0.96 mmol] in 5
</para>
3238

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry

Article
<para sub=“exp”>
mL of benzyl alcohol) was added at room temperature and the mixture
was stirred for 24 h. The solvent was then evaporated, water was added
(25 mL), and the mixture was extracted with dichloromethane (3 × 25
mL). The organic layer was dried on MgSO4 and evaporated under
reduced pressure, providing the desired compound (45 mg, 56%).
Characterization data are consistent with ref 17.
General procedure for compounds 1i−o: To a solution of the
corresponding compound 3 (1 mmol) in methanol (60 mL),
purchased sodium methoxide (4 mmol) was added and the mixture
was stirred at room temperature for 48 h. The solvent was then
evaporated, water was added (25 mL), and the mixture was extracted
with dichloromethane (3 × 25 mL). The organic layer was dried on
MgSO4 and evaporated under reduced pressure, providing the desired
compound.

1-Benzyl-3-[(1Z)-3,3-dimethyl-1-(methylsulfanyl)but-1-en-2-yl]-
1,3-dihydro-2H-benzimidazol-2-one, 1i. Yield: 100% (239 mg). Pale
yellow oil. 1H NMR (400 MHz, CDCl3): δ 1.22 (9H, s, CH3), 2.21
(3H, s, SCH3), 5.02 (1H, d, JAB = 15.8, CH2), 5.15 (1H, d, JAB = 15.9,
CH2), 6.40 (1H, s, H5), 6.78−6.86 (2H, m, arom), 6.91−7.01 (2H, m,
arom), 7.17−7.32 (5H, m, arom). 13C NMR (100 MHz, CDCl3): δ
16.6, 29.5, 38.8, 44.9, 108.5, 109.4 (2C), 121.3, 121.5, 127.4 (2C),
127.6, 128.8 (2C), 129.2, 129.6, 136.5, 137.9, 153.5. HRMS m/z calcd
C21H24N2OS+ [M + H]+: 353.1682; found 353.1684.

1-[3,5-Bis(triﬂuoromethyl)benzyl]-3-[(1Z)-3,3-dimethyl-1-
(methylsulfanyl)but-1-en-2-yl]-1,3-dihydro-2H-benzimidazol-2-one,
1j. Yield: 100% (313 mg). White solid. Mp = 143 °C. 1H NMR (400
MHz, CDCl3): δ 1.27 (9H, s, CH3), 2.25 (3H, s, SCH3), 5.05 (1H, d,
JAB = 16.3, CH2), 5.41 (1H, d, JAB = 16.2, CH2), 6.45 (1H, s, H5),
6.81−6.84 (1H, m, arom), 6.91−6.94 (1H, m, arom), 7.01−7.10 (2H,
m, arom), 7.77 (1H, s, arom), 7.80 (2H, s, arom). 13C NMR (150
MHz, CDCl3): δ 16.4, 29.4 (3C), 38.7, 43.9, 107.8, 109.9, 121.8, 121.9,
122.1, 123.3 (2C, q, J = 273), 127.6 (2C), 128.9, 129.6, 130.0, 132.2,
+
(2C, q, J = 33), 138.0, 139.4, 153.4. HRMS m/z calcd C23H22N2OSF6
[M + H]+: 489.1430; found 489.1432.

1-Methyl-3-[(Z)-2-(methylsulfanyl)-1-phenylethenyl]-1,3-dihydro-
2H-benzimidazol-2-one, 1k. Yield: 100% (43 mg). White crystals. Mp
= 168 °C. 1H NMR (300 MHz, CDCl3): δ 2.41 (3H, s, SCH3), 3.51
(3H, s, NCH3), 6.73 (1H, d, J = 7.8, arom), 6.97−7.32 (9H, m, arom
+H5). 13C NMR (75 MHz, CDCl3): δ 17.3, 27.6, 107.8, 109.5, 121.6,
122.0, 124.7 (2C), 128.0, 128.1, 128.4, 128.9 (2C), 130.6, 130.7, 135.5,
152.7. HRMS m/z calcd C17H17N2OS+ [M + H]+: 297.1056; found
297.1056.

1-[(Z)-1-(4-Fluorophenyl)-2-(methylsulfanyl)ethenyl]-3-methyl-
1,3-dihydro-2H-benzimidazol-2-one, 1l. Yield: 100% (51 mg).
Colorless oil. 1H NMR (300 MHz, CDCl3): δ 2.40 (3H, s, SCH3),
3.50 (3H, s, NCH3), 6.72 (1H, d, J = 7.7, arom), 6.91−7.28 (8H, m,
arom+H5). 13C NMR (75 MHz, CDCl3): δ 17.3, 27.6, 107.9, 109.4,
115.8, 116.1, 121.6, 122.1, 126.5, 126.6, 127.3, 128.2, 130.3, 130.6,
131.9, 152.6, 162.7 (d, J = 250.6). HRMS m/z calcd C17H16N2OSF+
[M + H]+: 315.0961; found 315.0962.

1-[(Z)-1-(4-Chlorophenyl)-2-(methylsulfanyl)ethenyl]-3-methyl-
1,3-dihydro-2H-benzimidazol-2-one, 1m. Yield: 100% (49 mg).
Yellow oil. 1H NMR (300 MHz, CDCl3): δ 2.41 (3H, s, SCH3), 3.51
(3H, s, NCH3), 6.71 (1H, d, J = 7.7, arom), 6.98−7.29 (8H, m, arom
+H5). 13C NMR (75 MHz, CDCl3): δ 17.3, 27.6, 107.9, 109.4, 121.7,
122.1, 126.0 (2C), 127.0, 128.1, 129.1 (2C), 130.6, 131.5, 133.8, 134.1,
152.5. HRMS m/z calcd C17H16N2OSCl+ [M + H]+: 331.0666; found
331.0666.

1-[(Z)-1-(4-Methoxyphenyl)-2-(methylsulfanyl)ethenyl]-3-methyl-
1,3-dihydro-2H-benzimidazol-2-one, 1n. Yield: 100% (61 mg). Pale
brown oil. 1H NMR (300 MHz, CDCl3): δ 2.38 (3H, s, SCH3), 3.50
(3H, s, NCH3), 3.77 (3H, s, OCH3), 6.72 (1H, d, J = 7.6, arom),
6.76−7.21 (8H, m, arom + H5). 13C NMR (75 MHz, CDCl3): δ 17.3,
27.5, 55.4, 107.7, 109.5, 114.3 (2C), 121.5, 121.9, 126.1 (2C), 128.0,
128.2, 128.3, 128.5, 130.6, 152.7, 159.6. HRMS m/z calcd
C18H19N2O2S+ [M + H]+: 327.1161; found 327.1161.

1-Methyl-3-[(Z)-2-(methylsulfanyl)-1-(naphthalen-2-yl)ethenyl]-
1,3-dihydro-2H-benzimidazol-2-one, 1o. Yield: 95% (21 mg). Pale
brown oil. 1H NMR (300 MHz, CDCl3): δ 2.45 (3H, s, SCH3), 3.55
(3H, s, NCH3), 6.74 (1H, d, J = 7.7, arom), 6.95−7.82 (11H, m, arom
+ H5). 13C NMR (75 MHz, CDCl3): δ 17.4, 27.6, 107.8, 109.5, 121.6,

122.0, 122.7, 123.6, 126.3, 126.6, 127.7, 128.2, 128.4, 128.5, 128.7,
130.7, 131.3, 132.8, 133.1, 133.6, 152.7. HRMS m/z calcd
C21H19N2OS+ [M + H]+: 347.1212; found 347.1212.

Synthesis of Benzimidazol-2-one 2. General procedure for
compounds 2a and 2e: To a solution of the corresponding compound
4 (1 mmol) in methanol (for 2a, 50 mL; for 2e, 70 mL), purchased
sodium methoxide (for 2a, 1.1 mmol; for 2e, 5 mmol) was added and
the mixture was stirred (for 2a, 40 °C for 5 h; for 2e, reﬂux for 3 h).
The solvent was then evaporated, water was added (25 mL), and the
mixture was extracted with dichloromethane (3 × 25 mL). The
organic layer was dried on MgSO4 and evaporated under reduced
pressure, providing the desired compound.
1-Methyl-3-[2-(methylsulfanyl)phenyl]-1,3-dihydro-2H-benzimi-
dazol-2-one, 2a. Yield: 77% (50 mg). Pale brown solid; Mp = 127−
129 °C. 1H NMR (400 MHz, CD3OD): δ 2.39 (3H, s, SCH3), 3.50
(3H, s, NCH3), 6.64 (1H, d, J = 7.9, arom), 7.06 (1H, t, J = 7.7, arom),
7.15−7.25 (2H, m, arom), 7.31−7.39 (2H, m, arom), 7.51−7.58 (2H,
m, arom). 13C NMR (100 MHz, CDCl3): δ 15.5, 27.5, 107.7, 108.9,
121.5, 122.0, 126.0, 126.8, 129.6, 129.8, 129.9, 130.4, 132.0, 139.2,
153.5. HRMS m/z calcd C15H15N2OS + [M + H]+: 271.0900; found
271.0900.

1-Benzyl-3-[5-chloro-2-(methylsulfanyl)phenyl]-1,3-dihydro-2H-
benzimidazol-2-one, 2e. Yield: 100% (163 mg). White solid. Mp =
159 °C. 1H NMR (400 MHz, CDCl3): δ 2.40 (3H, s, SCH3), 5.11
(1H, d, JAB = 15.8, CH2), 5.21 (1H, d, JAB = 15.8, CH2), 6.69−6.72
(1H, m, arom), 6.91−6.94 (1H, m, arom), 6.99−7.07 (2H, m, arom),
7.27−7.42 (7H, m, arom), 7.46 (1H, dd, J = 8.5, J = 2.3, arom). 13C
NMR (100 MHz, CDCl3): δ 15.7, 45.2, 108.8, 108.9, 121.7, 122.3,
127.6 (2C), 127.9, 128.0, 128.9 (2C), 129.5, 129.6, 129.9, 130.1, 131.4,
132.9, 136.2, 138.1, 153.2. HRMS m/z calcd C21H18N2OSCl+ [M +
H]+: 381.0823; found 381.0823.
General procedure for compounds 2b−c and 2g: To a solution of
the corresponding compound 4 (1 mmol) in methanol (for 2b and 2c,
40 mL; for 2g, 146 mL), purchased sodium methoxide (for 2b, 2.4
mmol; for 2c, 5 mmol; for 2g, 2 mmol) was added, and the mixture
was stirred (for 2b, 40 °C, overnight; for 2c, reﬂux for 4 h; for 2g, 40
°C for 1 h). The solvent was then evaporated, and the crude was
puriﬁed by column chromatography (eluent CH2Cl2/AcOEt 10:0 →
9:1), providing the desired compound.

1-(4-Chlorobenzyl)-3-[2-(methylsulfanyl)phenyl]-1,3-dihydro-2H-
benzimidazol-2-one, 2b. Yield: 98% (95 mg). White solid. Mp = 154
°C. 1H NMR (400 MHz, CDCl3): δ 2.41 (3H, s, SCH3), 5.07 (1H, d,
JAB = 15.8, NCH2), 5.99 (1H, d, JAB = 15.9, NCH2), 6.68−6.71 (1H,
m, arom), 6.87−6.91 (1H, m, arom), 6.99−7.07 (2H, m, arom), 7.29−
7.43 (7H, m, arom), 7.46−7.51 (1H, m, arom). 13C NMR (100 MHz,
CDCl3): δ 15.5, 44.4, 108.4, 109.0, 121.7, 122.0, 126.0, 126.9, 129.0
(2C), 129.1 (2C), 129.2, 129.6, 129.9, 130.0, 131.7, 133.6, 134.9,
139.2, 153.3. HRMS m/z calcd C21H18N2OSCl+ [M + H]+: 381.0823;
found 381.0825.

1-[5-Chloro-2-(methylsulfanyl)phenyl]-3-methyl-1,3-dihydro-2H-
benzimidazol-2-one, 2c. Yield: 72% (110 mg). Pale yellow oil. Mp =
184 °C. 1H NMR (400 MHz, CDCl3): δ 2.38 (3H, s, SCH3), 3.51
(3H, s, NCH3), 6.70 (1H, br d, J = 8.3, arom), 7.03−7.07 (2H, m,
arom), 7.14−7.18 (1H, m, arom), 7.31−7.34 (1H, m, arom), 7.35 (1H,
d, J = 2.0, arom), 7.44 (1H, dd, J = 8.6, J = 2.2, arom). 13C NMR (100
MHz, CDCl3): δ 15.7, 27.6, 107.9, 108.9, 121.7, 122.3, 127.9, 129.4,
129.8, 130.1, 130.4, 131.3, 132.9, 138.0, 153.2. HRMS m/z calcd
C15H14N2OSCl+ [M + H]+: 305.0510; found 305.0506.

1-[5-Chloro-2-(methylsulfanyl)phenyl]-3-heptyl-1,3-dihydro-2H-
benzimidazol-2-one, 2g. Yield: 50% (80 mg). White solid. Mp = 75
°C. 1H NMR (400 MHz, CDCl3): δ 0.87 (3H, br t, J = 6.9, CH3),
1.24−1.46 (8H, m, 4CH2), 1.77−1.86 (2H, m, CH2), 3.89−4.01 (2H,
m, NCH2), 6.70 (1H, d, J = 7.7, arom), 7.04 (1H, t, J = 7.6, arom),
7.07 (1H, d, J = 8.2, arom), 7.14 (1H, t, J = 7.6, arom), 7.32 (1H, d, J =
8.6, arom), 7.36 (1H, d, J = 2.1, arom), 7.44 (1H, dd, J = 8.5, J = 2.2,
arom). 13C NMR (100 MHz, CDCl3): δ 14.2, 15.7, 22.7, 26.9, 28.4,
29.1, 31.9, 41.5, 108.1, 108.9, 121.4, 122.1, 128.0, 129.5, 129.8, 129.9,
130.0, 131.3, 133.0, 138.1, 153.0. HRMS m/z calcd C21H26N2OSCl+
[M + H]+: 389.1449; found 389.1452.
</para>
3239

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

The Journal of Organic Chemistry

Article
<para sub=“exp”>
1-[5-Chloro-2-(ethylsulfanyl)phenyl]-3-methyl-1,3-dihydro-2H-
benzimidazol-2-one, 2d. To a solution of 2-chloro-6-methyl[3,1]-
benzimidazo[2,1-b][1,3]benzothiazol-6-ium 4-methylbenzenesulfonate
4c (238 mg, 0.54 mmol) in ethanol (5 mL), 5 mL of a freshly prepared
solution of sodium ethoxide (prepared by addition of sodium [25.6
mg, 1.11 mmol] in 10 mL of ethanol) was added at 0 °C. The mixture
was allowed to warm to room temperature overnight. The solvent was
then evaporated, water was added (25 mL), and the mixture was
extracted with dichloromethane (3 × 25 mL). The organic layer was
dried on MgSO4 and evaporated under reduced pressure, providing
the desired compound (145 mg).Yield: 81%. White solid. Mp = 101
°C. 1H NMR (400 MHz, CDCl3): δ 1.21 (3H, t, J = 7.4, CH3), 2.78−
2.91 (2H, m, SCH2), 3.51 (3H, s, NCH3), 6.67−6.71 (1H, m, arom),
7.02−7.08 (2H, m, arom), 7.13−7.18 (1H, m, arom), 7.34−7.37 (1H,
m, arom), 7.40−7.43 (2H, m, arom). 13C NMR (100 MHz, CDCl3): δ
14.0, 27.4, 27.5, 107.8, 108.8, 121.6, 122.2, 129.9 (2C), 130.2, 130.3,
132.0, 134.1, 136.5, 153.3. HRMS m/z calcd C16H16N2OSCl+ [M +
H]+: 319.0666; found 319.0665.

1-Benzyl-3-[5-chloro-2-(ethylsulfanyl)phenyl]-1,3-dihydro-2H-
benzimidazol-2-one, 2f. To a solution of 6-benzyl-2-chloro[3,1]-
benzimidazo[2,1-b][1,3]benzothiazol-6-ium bromide 4e (100 mg, 0.23
mmol) in ethanol (40 mL), 7 mL of a freshly prepared solution of
sodium ethoxide (prepared by addition of sodium [73 mg, 1.11 mmol]
in 40 mL of ethanol) was added at 40 °C. The mixture was allowed to
cool to room temperature overnight. The solvent was then evaporated,
water was added (25 mL), and the mixture was extracted with
dichloromethane (3 × 25 mL). The organic layer was dried on MgSO4
and evaporated under
reduced pressure, providing the desired
compound (81 mg). Yield: 89%. Yellow oil. 1H NMR (400 MHz,
CDCl3): δ 1.22 (3H, t, J = 7.3, CH3), 2.79−2.92 (2H, m, CH2), 5.11
(1H, d, JAB = 15.6, NCH2), 5.22 (1H, d, JAB = 15.6, NCH2), 6.70 (1H,
d, J = 7.1, arom), 6.92 (1H, d, J = 7.1, arom), 6.98−7.07 (2H, m,
arom), 7.27−7.47 (8H, m, arom). 13C NMR (100 MHz, CDCl3): δ
14.0, 27.6, 45.2, 108.8, 108.9, 121.7, 122.2, 127.7 (2C), 127.9, 128.9
(2C), 129.5, 129.8, 129.9, 130.0, 130.6, 132.1, 134.3, 136.3, 136.6,
153.3. HRMS m/z calcd C22H20N2OSCl+ [M + H]+: 395.0979; found
395.0975.
</para>
■ ASSOCIATED CONTENT
*S Supporting Information
1H NMR and 13C NMR spectra for all new compounds and
compounds described in ref 17; X-ray analysis of 1k. This
material is available free of charge via the Internet at http://
pubs.acs.org.

■ AUTHOR INFORMATION
Corresponding Authors
*E-mail: daniel.farran@univ-amu.fr.
*E-mail: christian.roussel@univ-amu.fr.
Notes
The authors declare no competing ﬁnancial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge OSEO (A0607008UAT), Aix-
Marseille University, and the CNRS (iSm2-UMR 7313) for
funding this research. We thank W. Bergachi and S. Aboudou
for
starting materials and Dr. M. Giorgi
(Spectropole) for X-ray structures.

synthesis of

■ REFERENCES

(1) Duarte, C. D.; Barreiro, E. J.; Frage, C. A. M. Mini-Rev. Med.
Chem. 2007, 7, 1108.
(2) (a) Palin, R.; Clark, J. K.; Evans, L.; Houghton, A. K.; Jones, P. S.;
Prosser, A.; Wishart, G.; Yoshiizumi, K. Bioorg. Med. Chem. 2008, 16,
2829. (b) Clark, J. K.; Jones, P. S.; Palin, R.; Rosair, G.; Weston, M.
Tetrahedron 2008, 64, 3119. (c) Palin, R.; Bom, A.; Clark, J. K.; Evans,

L.; Feilden, H.; Houghton, A. K.; Jones, P. S.; Montgomery, B.;
Weston, M. A.; Wishart, G. Bioorg. Med. Chem. 2007, 15, 1828.
(3) (a) Smith, E. D.; Vinson, N. A.; Zhong, D.; Berrang, B. D.;
Catanzaro, J. L.; Thomas, J. B.; Navarro, H. A.; Gilmour, B. P.;
J.; Carroll, F.I. Bioorg. Med. Chem. 2008, 16, 822.
Deschamps,
(b) Sulima, A.; Folk, J.; Jacobson, A. E.; Rice, K. C. Synthesis 2007,
1547. (c) De Risi, C.; Piero Pollini, G.; Trapella, C.; Peretto, I.;
Ronzoni, S.; Giardina, G. A. M. Bioorg. Med. Chem. 2001, 9, 1871.
(d) Kawamoto, H.; Ozaki, S.; Itoh, Y.; Miyaji, M.; Arai, S.; Nakashima,
H.; Kato, T.; Ohta, H.; Iwasa, Y. J. Med. Chem. 1999, 42, 5061.
(4) (a) Monforte, A.-M.; Logoteta, P.; De Luca, L.; Iraci, N.; Ferro,
S.; Maga, G.; De Clerq, E.; Pannecouque, C.; Chimirri, A. Bioorg. Med.
Chem. 2010, 18, 1702. (b) Monforte, A.-M.; Logoteta, P.; Ferro, S.; De
Luca, L.; Iraci, N.; Maga, G.; De Clercq, E.; Pannecouque, C.;
Chimirri, A. Bioorg. Med. Chem. 2009, 17, 5962. (c) Monforte, A.-M.;
Rao, A.; Logoteta, P.; Ferro, S.; De Luca, L.; Letizia Barreca, M.; Iraci,
N.; Maga, G.; De Clercq, E.; Pannecouque, C.; Chimirri, A. Bioorg.
Med. Chem. 2008, 16, 7429. (d) Letizia Barreca, M.; Rao, A.; De Luca,
L.; Iraci, N.; Monforte, A.-M.; Maga, G.; De Clercq, E.; Pannecouque,
C.; Balzarini, J.; Chimirri, A. Bioorg. Med. Chem. Lett. 2007, 17, 1956.
(5) (a) Hammach, A.; Barbosa, A.; Corbo Gaenzler, F.; Fadra, T.;
Goldberg, D.; Hao, M.-H.; Kroe, R. R.; Liu, P.; Qian, K. C.; Ralph, M.;
Sarko, C.; Soleymanzadeh, F.; Moss, N. Bioorg. Med. Chem. Lett. 2006,
16, 6316. (b) Dombroski, M. A.; Letavic, M. A.; McClure, K. F.;
Barberia, J. T.; Carty, T. J.; Cortina, S. R.; Csiki, C.; Dipesa, A. J.;
Elliott, N. C.; Gabel, C. A.; Jordan, C. K.; Labasi, J. M.; Martin, W. H.;
Peese, K. M.; Stock, I. A.; Svensson, L.; Sweeney, F. J.; Yu, C. H.
Bioorg. Med. Chem. Lett. 2004, 14, 919.
(6) (a) Combrink, K. D.; Gulzere, H. B.; Thuring, J. W.; Yu, K.-L.;
Civiello, R. L.; Zhang, Y.; Pearce, B. C.; Yin, Z.; Langley, D. R.; Kadow,
K. F.; Cianci, C. W.; Li, Z.; Clarke, J.; Genovesi, E. V.; Medina, I.;
Lamb, L.; Yang, Z.; Zadjura, L.; Krystal, M.; Meanwell, N. A. Bioorg.
Med. Chem. Lett. 2007, 17, 4784. (b) Alan Wang, X.; Cianci, C. W.; Yu,
K.-L.; Combrink, K. D.; Thuring, J. W.; Zhang, Y.; Civiello, R. L.;
Kadow, K. F.; Roach, J.; Li, Z.; Langley, D. R.; Krystal, M.; Meanwell,
N. A. Bioorg. Med. Chem. Lett. 2007, 17, 4592. (c) Yu, K.-L.; Alan
Wang, X.; Civiello, R. L.; Trehan, A. K.; Pearce, B. C.; Yin, Z.;
Combrink, K. D.; Gulzere, H. B.; Zhang, Y.; Kadow, K. F.; Cianci, C.
W.; Clarke, J.; Genovesi, E. V.; Medina, I.; Lamb, L.; Wyde, P. R.;
Krystal, M.; Meanwell, N. A. Bioorg. Med. Chem. Lett. 2006, 16, 1115.
(7) (a) Terefenko, E. A.; Kern, J.; Fensome, A.; Wrobel, J.; Zhu, Y.;
Cohen, J.; Winneker, R.; Zhang, Z.; Zhang, P. Bioorg. Med. Chem. Lett.
2005, 15, 3600. (b) Zhang, P.; Terefenko, E. A.; Wrobel, J.; Zhang, Z.;
Zhu, Y.; Cohen, J.; Marschke, K. B.; Mais, D. Bioorg. Med. Chem. Lett.
2001, 11, 2747.
(8) (a) Demont, E. H.; Bamborough, P.; Chung, C.; Craggs, P. D.;
Fallon, D.; Gordon, L. J.; Grandi, P.; Hobbs, C. I.; Hussain, J.; Jones,
E. J.; Le Gall, A.; Michon, A.-M.; Mitchell, D. J.; Prinjha, R. K.;
Roberts, A. D.; Sheppard, R. J.; Watson, R. J. ACS Med. Chem. Lett.
2014, 5, 1190. (b) Miah, A. H.; Abas, H.; Begg, M.; Marsh, B. J.;
O’Flynn, D. E.; Ford, A. J.; Percy, J. M.; Procopiou, P. A.; Richards, S.
A.; Rumley, S.-A. Bioorg. Med. Chem. 2014, 22, 4298. (c) O’Reilly, M.
C.; Scott, S. A.; Brown, H. A.; Lindsley, C. W. Bioorg. Med. Chem. Lett.
2014, 24, 5553. (d) Shim, H. J.; Yang, H. R.; Kim, H. I.; Kang, S.-A.;
No, K. T.; Jung, Y. H.; Lee, S.-T. Bioorg. Med. Chem. Lett. 2014, 24,
4659. (e) Wang, W.; Cao, H.; Wolf, S.; Camacho-Horvitz, M. S.;
Holak, T. A.; Dömling, A. Bioorg. Med. Chem. 2013, 21, 3982.
(f) Fukaya, T.; Kodo, T.; Ishiyama, T.; Nishikawa, T.; Baba, S.;
Masumoto, S. Bioorg. Med. Chem. 2013, 21, 1257. (g) Sun, Y.; Pandit,
B.; Chettiar, S. M.; Etter, J. P.; Lewis, A.; Johnsamuel, J.; Li, P.-K.
Bioorg. Med. Chem. Lett. 2013, 23, 4465. (h) Laube, M.; Kimple, S.;
Dietl, P.; Thome, U.; Wittekindt, O. Br. J. Pharmacol. 2013, 168, 1329.
(i) Taylor, S. J.; Padyana, A. K.; Abeywardane, A.; Liang, S.; Hao, M.-
H.; De Lombaert, S.; Proudfoot, J.; Farmer, B. S., III; Li, X.; Collins,
B.; Martin, L.; Albaugh, D. R.; Hill-Drzewi, M.; Pullen, S. S.;
Takahashi, H. J. Med. Chem. 2013, 56, 4465. (j) Berry, J. F.; Ferraris,
D. V.; Duvall, B.; Hin, N.; Rais, R.; Alt, J.; Thomas, A. G.; Rojas, C.;
Hashimoto, K.; Slusher, B. S.; Tsukamoto, T. ACS Med. Chem. Lett.
2012, 3, 839. (k) Yin, L. H.; Nemoto, P. A.; Mi Kim, J.; Hao, M.-H.;

3240

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

Article

The Journal of Organic Chemistry

Qian, K. C.; Farrow, N. A.; Albaugh, D. R.; Fowler, D. M.;
Scheiderman, R. D.; August, E. M.; Martin, L.; Hill-Drzewi, M.;
Pullen, S. S.; Takahashi, H.; De Lombaert, S. Bioorg. Med. Chem. Lett.
2011, 21, 4533. (l) Liu, W.; Lau, F.; Liu, K.; Wood, H. R.; Zhou, G.;
Chen, Y.; Li, Y.; Akiyama, T. E.; Castriota, G.; Einstein, M.; Wang, C.;
McCann, M. E.; Doebber, T. W.; Wu, M.; Chang, C. H.; McNamara,
L.; McKeever, B.; Mosley, R. T.; Berger, J. P.; Meinke, P. T. J. Med.
Chem. 2011, 54, 8541. (m) Budzik, B.; Garzya, V.; Shi, D.; Walker, G.;
Woolley-Roberts, M.; Pardoe, J.; Lucas, A.; Tehan, B.; Rivero, R. A.;
Langmead, C. J.; Wu, Z.; Forbes, I. T.; Jin, J. ACS Med. Chem. Lett.
2010, 1, 244. (n) Sivendran, S.; Jones, V.; Sun, D.; Wang, Y.;
Grzegorzewicz, A. E.; Scherman, M. S.; Napper, A. D.; McCammon, J.
A.; Lee, R. E.; Diamond, S. L.; McNeil, M. Bioorg. Med. Chem. 2010,
18, 896.
(9) (a) Mastalerz, M.; Oppel, I. Angew. Chem., Int. Ed. 2012, 51,
5252. (b) Schwiebert, K. E.; Chin, D. N.; MacDonald,
J. C.;
Whitesides, G. M. J. Am. Chem. Soc. 1996, 118, 4018.
(10) Mir, A. A.; Matsumura, S.; Hlil, A. R.; Hay, A. S. ACS Macro
Lett. 2012, 1, 194.
(11) Ward, R. E.; Meyer, T. Y. Macromolecules 2003, 36, 4368.
(12) Meanwell, N. A.; Sit, S. Y.; Gao, J.; Wong, H. S.; Gao, Q.;
Laurent, D. R.; Balasubramanian, N. J. Org. Chem. 1995, 60, 1565.
(13) (a) Li, Q.; Li, T.; Woods, K. W.; Gu, W.-Z.; Cohen, J.; Stoll, V.
S.; Galicia, T.; Hutchins, C.; Frost, D.; Rosenberg, S. H.; Sham, H. L.
Bioorg. Med. Chem. Lett. 2005, 15, 2918. (b) Kawamoto, H.;
Nakashima, H.; Kato, T.; Arai, S.; Kamta, K.; Iwasawa, Y. Tetrahedron
2001, 57, 981.
(14) (a) Gustin, D. J.; Sehon, C. A.; Wei, J.; Cai, H.; Meduna, S. P.;
Khatuya, H.; Sun, S.; Gu, Y.; Jiang, W.; Thurmond, R. L.; Karlsson, L.;
Edwards, J. P. Bioorg. Med. Chem. Lett. 2005, 15, 1687. (b) Poulain, R.;
Horvath, D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.;
Déprez, B. J. Med. Chem. 2001, 44, 3378.
(15) (a) Xu, X.-J.; Zong, Y.-X. Tetrahedron Lett. 2007, 48, 129.
(b) McLaughlin, M.; Palucki, M.; Davies, I. W. Org. Lett. 2006, 8,
3311. (c) Benedi, C.; Bravo, F.; Uriz, P.; Fernandez, E.; Claver, C.;
Castillon, S. Tetrahedron Lett. 2003, 44, 6073.
(16) (a) Li, Z.; Sun, H.; Jiang, H.; Liu, H. Org. Lett. 2008, 10, 3263.
(b) Barbero, N.; Carril, M.; SanMartin, R.; Dominguez, E. Tetrahedron
2008, 64, 7283. (c) Zou, B.; Yuan, Q.; Ma, D. Org. Lett. 2007, 9, 4291.
(17) Roussel, C.; Andreoli, F.; Vanthuyne, N. International Patent
WO 2010/052670 A1, May 14, 2010.
(18) Kuethe, J. T.; Varon, J.; Childers, K. G. Tetrahedron 2007, 63,
11489 and references cited therein..
(19) (a) Al-Rashood, K. A.; Abdel-Aziz, H. A. Molecules 2010, 15,
3775. (b) Xu, H.; Zhang, Y.; Huang, J.; Chen, W. Org. Lett. 2010, 12,
3704. (c) Chimirri, A.; Grasso, S.; Romeo, G.; Zappala, M. Heterocycles
1988, 27, 1975.
(20) Roussel, C.; Andreoli, F.; Roman, M.; Hristova, M.; Vanthuyne,
N. Molecules 2005, 10, 327.
(21) Details are given in the Supporting Information.
(22) (a) Gao, J.; Zhu, J.; Chen, L.; Shao, Y.; Zhu, J.; Huang, Y.;
Wang, X.; Lv, X. Tetrahedron Lett. 2014, 55, 3367. (b) Kumar, R. K.;
Manna, S.; Mahesh, D.; Sar, D.; Punniyamurthy, T. Asian J. Org. Chem.
2013, 2, 843. (c) Zhang, X.; Jia, J.; Ma, C. Org. Biomol. Chem. 2012, 10,
7944.
(23) Bruncko, M.; Tahir, S. K.; Song, X.; Chen, J.; Ding, H.; Huth, J.
R.; Jin, S.; Judge, R. A.; Madar, D. J.; Park, C. H.; Park, C.-M.; Petros,
A. M.; Tse, C.; Rosenberg, S. H.; Elmore, S. W. Bioorg. Med. Chem.
Lett. 2010, 20, 7503.
(24) Badarau, E.; Suzenet, F.; Bojarski, A. J.; Guillaumet, G. Bioorg.
Med. Chem. Lett. 2009, 19, 1600.
(25) McKay, M. C.; Dworetzky, S. I.; Meanwell, N. A.; Olesen, S.-P.;
Reinhart, P. H.; Levitan, I. B.; Adelman, J. P.; Gribkoff, V. K. J.
Neurophysiol. 1994, 71, 1873.
(26) (a) Deady, L. W. Aust. J. Chem. 1981, 34, 163. (b) Kister, J.;
Berg, U.; Gallo, R.; Metzger, J. Bull. Soc. Chim. Fr. 1979, 484. (c) Berg,
U.; Gallo, R.; Metzger, J. J. Org. Chem. 1976, 41, 2621.

3241

DOI: 10.1021/acs.joc.5b00221
J. Org. Chem. 2015, 80, 3233−3241

